<li>amiloride<p>amiloride and triamterene both increase  serum potassium. Avoid or Use Alternate Drug.<span><br><br></span>amiloride, triamterene.
Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Hyperkalemia.</p></li><li>aminolevulinic acid<p>hydrochlorothiazide increases toxicity of aminolevulinic acid by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration of photosensitizing drugs may enhance the phototoxic reaction to photodynamic therapy with aminolevulinic acid.</p></li><li>amisulpride<p>amisulpride, hydrochlorothiazide. pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of hypokalemia.</p></li><li>carbamazepine<p>carbamazepine, hydrochlorothiazide.
Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased risk of systemic hyponatremia.</p></li><li>cisapride<p>hydrochlorothiazide, cisapride. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of prolonged QTc interval.</p></li><li>cyclophosphamide<p>hydrochlorothiazide increases toxicity of cyclophosphamide by decreasing renal clearance. Avoid or Use Alternate Drug. Increased myelosuppressive effects.</p></li><li>cyclosporine<p>cyclosporine, hydrochlorothiazide.
Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased risk of systemic hyponatremia.<span><br><br></span>triamterene and cyclosporine both increase  serum potassium. Avoid or Use Alternate Drug. Coadministration not recommended</p></li><li>dofetilide<p>hydrochlorothiazide increases levels of dofetilide by decreasing renal clearance. Contraindicated. Risk of prolonged QTc interval.</p></li><li>drospirenone<p>drospirenone and triamterene both increase  serum potassium. Avoid or Use Alternate Drug.<span><br><br></span>drospirenone, triamterene.
Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Hyperkalemia.</p></li><li>eplerenone<p>triamterene, eplerenone. Mechanism: pharmacodynamic synergism. Contraindicated. Hyperkalemia.</p></li><li>isocarboxazid<p>isocarboxazid, hydrochlorothiazide. Other (see comment). Contraindicated. 
Comment: Additive hypotensive effects may be seen when MAOI's are combined with antihypertensives.</p></li><li>methyl aminolevulinate<p>hydrochlorothiazide increases toxicity of methyl aminolevulinate by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration of photosensitizing drugs may enhance the phototoxic reaction to photodynamic therapy with aminolevulinic acid.</p></li><li>potassium acid phosphate<p>triamterene and potassium acid phosphate both increase  serum potassium. Avoid or Use Alternate Drug.</p></li><li>potassium chloride<p>triamterene and potassium chloride both increase  serum potassium. Avoid or Use Alternate Drug.</p></li><li>potassium citrate<p>triamterene and potassium citrate both increase  serum potassium. Avoid or Use Alternate Drug.</p></li><li>potassium phosphates, iv<p>triamterene and potassium phosphates, iv both increase  serum potassium. Avoid or Use Alternate Drug.</p></li><li>spironolactone<p>spironolactone and triamterene both increase  serum potassium. Avoid or Use Alternate Drug.<span><br><br></span>spironolactone, triamterene.
Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Hyperkalemia.</p></li><li>squill<p>hydrochlorothiazide increases toxicity of squill by Other (see comment). Avoid or Use Alternate Drug. 
Comment: Potassium depletion may enhance toxicity of squill.</p></li>